ASLAN003


Catalog No. Size PriceQuantity
M18317-C Contact sales@xcessbio.com for quotation $100Unavailable

Description

ASLAN003 is an orally active and potent Dihydroorotate Dehydrogenase (DHODH) inhibitor with an IC50 of 35 nM for human DHODH enzyme. ASLAN003 inhibits protein synthesis via activation of AP-1 transcription factors. ASLAN003 induces apoptosis and substantially prolongs survival in acute myeloid leukemia (AML) xenograft mice.

Product information

CAS Number: 1035688-66-4

Molecular Weight: 356.32

Formula: C19H14F2N2O3

Chemical Name: 2-({3,5-difluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}amino)pyridine-3-carboxylic acid

Smiles: COC1=CC(=CC=C1)C1=CC(F)=C(NC2=NC=CC=C2C(O)=O)C(F)=C1

InChiKey: OMPATGZMNFWVOH-UHFFFAOYSA-N

InChi: InChI=1S/C19H14F2N2O3/c1-26-13-5-2-4-11(8-13)12-9-15(20)17(16(21)10-12)23-18-14(19(24)25)6-3-7-22-18/h2-10H,1H3,(H,22,23)(H,24,25)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 130 mg/mL (364.84 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

ASLAN003 (0.01-100 μM; for 48 hours) inhibits leukemic cell proliferation. The cell viability is maintained at ~50% at ASLAN003 1 μM and higher. ASLAN003 (0.5, 1 μM; for 48 hours) significantly increases cleaved caspase 8. ASLAN003 (2, 4 μM; for 96 hours) decreases viability and induces differentiation in primary acute myeloid leukemia blasts and myelodysplastic syndrome samples. ASLAN003 (1, 2 μM; pretreatment 1 h before OPP for 1 h) inhibits protein synthesis, as demonstrated by the reduced incorporation of O-propargyl-puromycin (OPP) at protein translation sites in both MOLM-14 and KG-1 cells. ASLAN003 causes the downregulation of EIF4B, and RPL6 proteins.

In Vivo:

ASLAN003 (50 mg/kg; oral gavage; once daily; from the day 3 to 30) substantially reduces the number of disseminated tumors and prolongs survival.

Products are for research use only. Not for human use.

Payment & Security

PayPal Venmo

Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.

You may also like

Recently viewed